Cramer Rosenthal McGlynn Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CON
Concentra Group Holdings
CON
|
+$41.1M |
| 2 |
Elanco Animal Health
ELAN
|
+$22.6M |
| 3 |
Camden Property Trust
CPT
|
+$21.4M |
| 4 |
MASI
Masimo
MASI
|
+$19.4M |
| 5 |
Bank of Hawaii
BOH
|
+$18.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRCL
Stericycle Inc
SRCL
|
+$39M |
| 2 |
Burlington
BURL
|
+$34M |
| 3 |
Morningstar
MORN
|
+$23.6M |
| 4 |
LeMaitre Vascular
LMAT
|
+$20.5M |
| 5 |
SharkNinja
SN
|
+$19.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.36% |
| 2 | Financials | 16.57% |
| 3 | Industrials | 16.39% |
| 4 | Consumer Discretionary | 13.9% |
| 5 | Healthcare | 9.45% |
Similar funds
Cramer Rosenthal McGlynn's Q3 2024 Portfolio in Review
As of Q3 2024, Cramer Rosenthal McGlynn held 112 positions worth $1.8B, up 5.7% from $1.7B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Cramer Rosenthal McGlynn withdrew a net $65.5M in Q3 2024, closing 17 positions and reducing 43 holdings. Its most notable exit was Stericycle Inc, an estimated $39M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Financials and Industrials.
Against the trend, Cramer Rosenthal McGlynn opened a new position in Concentra Group Holdings worth $39.8M.
- Cramer Rosenthal McGlynn's largest Q3 2024 buy was Concentra Group Holdings: 1,781,286 shares worth $39.8M.
- Cramer Rosenthal McGlynn added most to Elanco Animal Health in Q3 2024, an estimated $22.6M increase.
- Cramer Rosenthal McGlynn's biggest Q3 2024 reduction was Burlington, cutting an estimated $34M.
- Cramer Rosenthal McGlynn fully exited Stericycle Inc in Q3 2024, selling an estimated $39M.
- Cramer Rosenthal McGlynn's ten largest holdings make up 24% of its $1.8B portfolio in Q3 2024.
- Cramer Rosenthal McGlynn opened 10 new positions and closed 17 in Q3 2024.
- Cramer Rosenthal McGlynn's portfolio value rose 5.7% quarter-over-quarter to $1.8B.
Based on Cramer Rosenthal McGlynn's 13F filing for Q3 2024, filed 14 Nov 2024.